Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
N Engl J Med
; 385(15): 1382-1392, 2021 10 07.
Article
in En
| MEDLINE
| ID: mdl-34260849
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antibodies, Monoclonal, Humanized
/
COVID-19 Drug Treatment
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
N Engl J Med
Year:
2021
Document type:
Article
Country of publication:
United States